Merz licenses TAU Alzheimer's drug

Merz is the developer of Memantine, an anti-dementia drug, as well as treatments for Parkinson's Disease and depression.

By YONI TEITZ
July 11, 2007 08:47
Merz licenses TAU Alzheimer's drug

pills 88. (photo credit: )

Tel Aviv University has licensed an Alzheimer's treatment it developed to Merz Pharmaceuticals, a German producer of Alzheimer's drugs. Ramot, Tel Aviv University's technology transfer company, raised $8.5 million for research into the treatment in 2003. Merz is the developer of Memantine, an anti-dementia drug, as well as treatments for Parkinson's Disease and depression.


Related Content

[illustrative photo]
September 24, 2011
Diabetes may significantly increase risk of dementia

By UNIVERSITY OF MICHIGAN HEALTH SYSTEM

Israel Weather
  • 11 - 21
    Beer Sheva
    12 - 20
    Tel Aviv - Yafo
  • 9 - 17
    Jerusalem
    12 - 17
    Haifa
  • 14 - 25
    Elat
    11 - 22
    Tiberias